Hematopoietic stem cell transplantation (HSCT) remains a definitive therapy for hematological malignancies and various genetic disorders. However, the procedure is inherently disruptive. Conditioning regimens, broad-spectrum antibiotics, and the transplant process itself often lead to profound "dysbiosis", a collapse of the gut microbial ecosystem.
Recent landmark literature, including the review "Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface"1, has illuminated a critical metabolic link: the depletion of short-chain fatty acids (SCFAs), particularly butyrate, is a primary driver of Graft-versus-Host Disease (GvHD) and poor immune recovery.
As a leading bio-CRO, Creative Biolabs provides the technical infrastructure and scientific expertise to help you translate these insights into clinical breakthroughs. From precise metabolomic profiling to complex GvHD animal models, our suite of services is designed to decode the host-microbiota interface.
Science Deep-Dive: How SCFAs Govern the HSCT Landscape1
The cited literature highlights three pillars of SCFA-mediated protection that are central to successful HSCT outcomes:
1. Reinforcement of the Intestinal Barrier
SCFAs, primarily acetate, propionate, and butyrate-are the preferred energy source for intestinal epithelial cells (IECs). In the context of HSCT:
-
Mechanism: Butyrate promotes the expression of tight junction proteins (ZO-1, Occludin) and stimulates mucin production.
-
The Problem: Post-conditioning dysbiosis reduces butyrate-producing taxa (e.g., Clostridiales), leading to a "leaky gut" that allows bacterial translocation, triggering systemic inflammation.
2. Immunomodulation via Treg Induction
The balance between pro-inflammatory Th17 cells and anti-inflammatory Regulatory T cells (Tregs) determines the severity of GvHD.
-
Mechanism: SCFAs act as Histone Deacetylase (HDAC) inhibitors and ligands for G-protein coupled receptors (GPR41, GPR43, GPR109A). This signaling environment promotes the differentiation of peripheral Foxp3+ Tregs.
-
Impact: Higher levels of systemic SCFAs correlate with reduced alloreactivity and improved survival in HSCT recipients.
3. Regulation of the Innate Immune Response
Beyond T cells, SCFAs influence myeloid cells and dendritic cells (DCs). By dampening the production of pro-inflammatory cytokines like IL-6, TNF-α, and IL-1β, SCFAs help maintain a state of "immune tolerance" necessary for the graft to thrive without attacking host tissues.
Our Comprehensive Service Portfolio
To match the rigorous demands of HSCT research, we offer a specialized "Microbiota-Immune Axis" service package.
High-Resolution Microbiome Profiling
Understanding who is in the gut is the first step.
-
16S rRNA Sequencing: Cost-effective identification of SCFA-producing families such as Lachnospiraceae and Ruminococcaceae.
-
Shotgun Metagenomics: Functional analysis of microbial genes. We track the abundance of butyrate kinase and other enzymes involved in SCFA synthesis pathways.
Concentration matters. We provide absolute quantification of SCFAs in diverse biological matrices.
-
Platforms: GC-MS (Gas Chromatography-Mass Spectrometry) and LC-MS/MS.
-
Analyte Scope: Acetate, Propionate, Butyrate, Valerate, Isovalerate, and branched-chain fatty acids (BCFAs).
-
Sample Types: Fecal matter, serum, plasma, and intestinal contents (mouse/human).
-
Specialty: High-sensitivity assays for systemic SCFA levels, which the literature confirms are key predictors of chronic GvHD.
Our laboratory is equipped with high-throughput anaerobic workstations and automated cultivation systems. We specialize in the isolation of "difficult-to-culture" anaerobes. Our services include strain characterization：
-
Antibiotic resistance profiling
-
Stability testing
-
Fermentation optimization.
-
Intestinal Epithelial Barrier Models: Specialized cell culture systems, such as Caco-2 or HT29-MTX monolayers, as well as patient-derived intestinal organoids (enteroids). These models are essential for measuring Trans-Epithelial Electrical Resistance (TEER) and quantifying tight junction protein expression following exposure to bacterial supernatants.
-
Immune Reporter Assays: High-throughput screens to verify HDAC inhibition via Western blot or fluorometric activity assays, along with co-culture systems utilizing human peripheral blood mononuclear cells (PBMCs) to monitor the differentiation of naive CD4+ T cells into Foxp3+ Treg cells via multi-color flow cytometry.
Why Choose Us: Our Competitive Advantages
Integrated "Multi-Omics" Approach
We don't just provide data; we provide correlation. We link microbial composition to SCFA levels and subsequently to immune phenotypes in a single, comprehensive report.
Expert Scientific Consultation
Our team includes PhD-level scientists specialized in mucosal immunology and microbiology who can help you design your study to align with current literature trends.
Animal Facilities
Ensuring the highest standards of ethics and data reproducibility for your preclinical trials.
Application Fields of This Service
Our services are tailored for:
-
Biopharmaceutical Companies: Developing microbial consortia (Live Biotherapeutic Products) to prevent GvHD.
-
Nutraceutical Manufacturers: Testing resistant starches and fiber-based prebiotics for post-transplant nutritional support.
-
Academic Research Groups: Investigating the molecular mechanisms of the SCFA-GPR receptor axis.
-
Cell Therapy Developers: Enhancing the "fitness" of stem cell grafts through metabolic modulation of the host environment.
Partnering for Clinical Discovery
As an academic and technical partner, our role is to standardize these complex variables. By outsourcing these specialized processes to a CRO with dedicated expertise in LBPs and gut microbiota, research organizations can ensure that their projects are built on a foundation of rigorous, high-quality data. Creative Biolabs is committed to supporting this scientific frontier by providing the technical infrastructure and expertise required to navigate these complexities. We invite researchers, clinical investigators, and biopharmaceutical developers to consult with our technical team. Whether you require precise SCFA quantification, anaerobic strain isolation, or the execution of a GvHD mouse model study, we offer the "academic partner" collaboration needed to advance your microbiota-based programs.
Contact our technical consultants today to discuss your project requirements or to request a detailed service proposal for your LBP and HSCT research initiatives.
Frequently Asked Questions (FAQs)
Why focus on SCFAs specifically for HSCT research?
As noted in the literature, SCFAs are the primary functional link between the microbiota and the immune system. They are easier to standardize as biomarkers or therapeutic agents (postbiotics) than whole bacterial communities.
Can you measure SCFAs in frozen samples?
Yes. We have validated stability protocols for samples stored at -80°C. We also provide specialized collection kits with stabilizers to ensure the integrity of volatile fatty acids from the point of collection.
What is the typical turnaround time for a metagenomics + SCFA project?
Typically 4-6 weeks from sample receipt to the final integrated bioinformatic report.
Reference
-
Hajjar, Crystel et al. "Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface." Frontiers in microbiology 17 1754099. 6 Feb. 2026, doi:10.3389/fmicb.2026.1754099. Distributed under Open Access license CC BY 4.0, without modification.
